Reference health
Current status and future direction in the management of malignant melanoma
80/80 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 80 checked references that resolve
resolves10.1002/(SICI)1097-0142(19990715)86:2<288::AID-CNCR13>3.0.CO;2-S
Classification of cutaneous malignant melanoma
resolves10.1016/j.ejca.2016.05.005
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
resolves10.1016/j.nano.2014.11.006
Recent advances in targeted nanoparticles drug delivery to melanoma
resolves10.3892/ol.2013.1345
Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model
resolves10.1634/theoncologist.2010-0190
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
resolves10.1200/JCO.1999.17.9.2745
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
resolves10.1200/JCO.2004.04.165
Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
resolves10.1111/j.1755-148X.2009.00630.x
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma
resolves10.1200/JCO.1996.14.1.7
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
resolves10.1016/S0305-7372(03)00074-4
Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials
resolves10.1007/s00262-013-1428-4
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)
resolves10.1016/j.ejca.2011.09.028
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
resolves10.1038/sj.bjc.6601320
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
resolves10.1371/journal.pone.0035650
Resveratrol Prevents Endothelial Cells Injury in High-Dose Interleukin-2 Therapy against Melanoma
resolves10.3389/fgene.2013.00066
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
resolves10.1158/0008-5472.CAN-08-1430
BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
resolves10.1038/nature08902
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
resolves10.1016/S1470-2045(14)70012-9
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
resolves10.1056/NEJMoa1103782
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
resolves10.1016/S1470-2045(12)70431-X
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
resolves10.1200/JCO.2013.49.8691
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
resolves10.1016/S0140-6736(12)60398-5
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
resolves10.2146/ajhp140045
Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma
resolves10.1038/sj.onc.1210422
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
resolves10.1056/NEJMoa1112302
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
resolves10.1016/S0140-6736(12)60868-X
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
resolves10.1158/1535-7163.MCT-12-0530
Intratumoral Molecular Heterogeneity in a <i>BRAF</i>-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
resolves10.1200/JCO.2012.44.7888
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
resolves10.1038/bjc.2014.139
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
resolves10.1016/j.ccr.2012.10.009
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
resolves10.1073/pnas.0900780106
<sup>V600E</sup>
BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
resolves10.1038/nature08833
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
resolves10.1007/s00262-012-1227-3
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
resolves10.1634/theoncologist.13-S4-16
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
resolves10.1056/NEJMoa1104621
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
resolves10.1093/annonc/mdt161
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
resolves10.1056/NEJMoa1200690
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
resolves10.1007/s00262-014-1647-3
Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma
resolves10.1056/NEJMoa1412082
Nivolumab in Previously Untreated Melanoma without
<i>BRAF</i>
Mutation
resolves10.1007/s10147-007-0751-1
Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update
resolves10.1200/JCO.2012.47.7836
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
resolves10.1200/JCO.2010.33.9275
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring
<i>c-Kit</i>
Mutation or Amplification
resolves10.1002/cncr.26724
<i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma
resolves10.1016/S1470-2045(13)70024-X
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
resolves10.1158/0008-5472.CAN-13-1825
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
resolves10.1038/nm.2941
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
resolves10.1371/journal.pone.0038364
Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
resolves10.2174/138920012802850074
Nanoparticles Improve Biological Functions of Phthalocyanine Photosensitizers Used for Photodynamic Therapy
resolves10.1039/c2cs15344k
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
resolves10.1248/bpb.b12-00817
Systemic Delivery of Small Interfering RNA by Use of Targeted Polycation Liposomes for Cancer Therapy
resolves10.1016/j.canlet.2014.12.050
Advances in targeted therapy for unresectable melanoma: New drugs and combinations
resolves10.1021/bc2005945
Lysosomal Delivery of a Lipophilic Gemcitabine Prodrug Using Novel Acid-Sensitive Micelles Improved Its Antitumor Activity
resolves10.1016/j.biomaterials.2010.07.005
Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin
resolves10.3402/nano.v5.24381
Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma
resolves10.1615/JEnvironPatholToxicolOncol.v26.i3.10
A New Method for Photodynamic Therapy of Melanotic MelanomaEffects of Depigmentation with Violet Light Photodynamic Therapy
resolves10.1016/S1011-1344(98)00071-2
Photoinactivation of amelanotic and melanotic melanoma cells sensitized by axially substituted Si-naphthalocyanines
resolves10.1038/nm.2933
In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers
resolves10.1158/0008-5472.CAN-05-1343
A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas
resolves10.1016/j.cell.2010.04.020
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
The 3 references without a DOI — listed, not checked
no DOI — not checkedCurrent and future roles of targeted therapy and immunotherapy in advanced melanoma
no DOI — not checkedDrug resistance in human melanoma: mechanisms and therapeutic opportunities
no DOI — not checkedTrametinib: a MEK inhibitor for management of metastatic melanoma
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1097/cmr.0000000000000379"><img src="https://citestamp.com/citestamped/10.1097/cmr.0000000000000379/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1097/cmr.0000000000000379)